Value-based pricing for new medicines, proposed as part of UK health care reform, would create a QALY-plus approach for drugs approved starting 1 January 2014. For new drugs, this would replace the current PPRS system. The implications for pricing and reimbursement, and innovation, are outlined by Prof Towse in this blog post.

Members of the OHE team participated in a number of sessions at ISPOR’s 13th Annual European Congress in November. This post summarizes the contributions of Prof Nancy Devlin, OHE’s Director of Research.

At a recent OHE seminar, Prof Ben Martin (Science and Technology Policy Studies at SPRU, University of Sussex) presented the results of his extensive literature review and qualitative research on how the field of science policy research has evolved and advanced in the 50 years since its inception.

OHE Consulting has released new research on orphan medicinal products (OMPs) in Europe that assesses the effects of the European Union’s 1999 Regulation on Orphan Medicinal Products on the European economy and society.

The OHE recently published reports on the vaccines markets in Australia and in the UK, originally prepared as case studies for a project funded by the Federal German Ministry of Health (Bundesgesundheitsministerium). The main findings of the Australian study are outlined in this post.